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ABSTRACT 
Objective: A combination of the Floating-Bioadhesive system will overcome the drawbacks of floating & bioadhesive systems if used alone and will 
have a significant effect on improving the therapeutic effect of the drug involved. The present study involves the formulation and in vitro evaluation 
of atenolol floating-Bioadhesive tablet for prolonged residence in the stomach for the treatment of hypertension.  
Methods: The tablets were prepared by direct compression method using directly compressible polymers such as, Hydroxy Propyl Methyl Cellulose (HPMC) 
K15M, Guar gum, Carbopol, and sodium alginate. The tablets were evaluated for buoyancy test, mucoadhesion force, swelling study, drug content, ex-vivo 
mucoadhesion strength and in-vitro release profile. Sodium bicarbonate was used for producing the effervescent base for the buoyancy of tablets.  
Results: Formulation batch contains sodium alginate which has shown highest percentage cumulative drug release up to 99.12%. No significant change was 
observed in physical appearance, drug content, float ability or in vitro dissolution pattern after storage at 45 °C/75% RH for three months. 
Conclusion: In this present research work it was concluded that the cumulative drug release increased when the viscosity and concentration of the polymer 
was increased.
Keywords: Hypertension, Ex vivo mucoadhesion strength, Carbopol, Atenolol. 
 The swelling properties were increased with increasing polymer concentration and contributed to the drug release from the tablet matrix.  
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
 
INTRODUCTION 
Many orally-administered drugs display poor bioavailability when 
administered as conventional dosage form, i.e. the rate and extent to 
which the drugs are absorbed is less than desirable. With several 
drugs, absorption may be as little as 30% or less of the orally 
administered dose. To compensate for this effect, a very large dose is 
often administered so that absorption of the therapeutically 
required quantity of the drug can occur. This technique may prove 
costly with expensive drugs, and the unabsorbed drug may also have 
undesirable side effect within the gastrointestinal tract. In addition, 
poorly absorbed drug often display large inter and intra-subject 
variability in bioavailability. This problem may be overcome by 
modified release drug delivery system with a prolonged residence 
time in the stomach [1]. Atenolol is a cardioselective β-blocker 
widely prescribed for an asymptomatic condition such as 
hypertension. It is poorly absorbed from the lower gastrointestinal 
tract. The oral bioavailability of atenolol was reported to be 50% [2]. 
The human jejunal permeability and extent of absorption is low [3]. 
Thus, it seems that an in gastric residence time may increase the 
extent of absorption and bioavailability of the drug. The 
recommended adult oral dosage of atenolol is 50 mg twice daily for 
the effective treatment of hypertension. However, fluctuations of 
drug concentration in plasma may occur, resulting in side effects or 
a reduction in drug concentration at receptor side. As the drug is 
effective when the plasma fluctuations are minimized, therefore 
sustained release dosage form of atenolol is desirable. The short 
biological half-life of drug (6 to 8 h) also favors the development of 
sustained release formulations. In this study, an effervescent floating 
system and bioadhesive system were used in combination. Floating 
dosage forms are meant to remain floating on the gastric fluid when 
the stomach is full after a meal. However, as the stomach empties 
and the tablet reaches the pylorus, the buoyancy of the dosage form 
may be reduced. It may be that the dosage form will then pass 
through the pylorus into the small intestine. Thus, the buoyancy of 
an FDDS in the stomach may be limited to only 3–4 h. Furthermore, 
floating systems do not always release the drug at the intended site. 
In a bioadhesive drug delivery system, it is quite likely that the 
system becomes dislodged from the stomach mucosa wall when the 
system is full and the semi-liquid contents are churning around due 
to the effect of peristalsis [4]. A floating-Bioadhesive system would 
overcome these drawbacks of floating and Bioadhesive systems and 
would have a significant effect on improving the therapeutic effect of 
the drug involved [5]. 
MATERIALS AND METHODS 
The present study involves the formulation 
and in vitro evaluation of atenolol floating-Bioadhesive tablet for 
prolonged residence in the stomach for the treatment of 
Hypertension. 
Atenolol was supplied as a gift sample from GVK Pharma, Hyderabad. 
Micro Crystalline Cellulose (MCC), HPMC K15M and Sodium alginate 
were brought from Signet chemical corporation, Mumbai. Sodium 
bicarbonate and Carbopol obtained from Loba Chem. Pvt. Ltd., 
Mumbai. Guar gum was supplied from Noveon chemicals, Mumbai.  
Pre-formulation studies  
Drug-excipient compatibility studies 
The drug and excipients must be compatible with one another to 
produce a product that is stable, efficacious, attractive, easy to 
administer and safe. The compatibility studies provide the 
framework for the drugs combination with excipients in the 
fabrication of the dosage form. The study was carried out to 
establish that the therapeutically active drug has not undergone any 
changes after it has been subjected to processing steps during 
formulation of tablets. Compatibility studies were carried out by 
mixing definite proportions of drug and excipient and kept in glass vials, 
which are stored at 55 °C (2 w) and 40±2 °C/75±5 % RH (4 w)[6]. 
Differential scanning calorimetry (DSC) 
The DSC analysis was carried out using Differential Scanning 
Calorimeter (SDT 2960 TA Instrument, USA). Samples were placed 
in a platinum crucible, and the DSC thermograms were recorded at a 
heating rate of 10 °C/min in the rage 20 °C to 350 °C, at a nitrogen 
flow of 20 ml/min. 
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Calibration curves for atenolol 
A standard graph of pure drug in the suitable medium was prepared 
by plotting the concentration on X-axis and absorbance on Y-axis. An 
accurately weighed 100 mg of Atenolol was dissolved in 0.1N HCl as 
per I. P and make up the volume up to 100 ml in a volumetric flask, 
(Stock Solution I: 1 mg/ml or 1000 μg/ml). From this stock solution 
I, 10 ml of solution was pipetted out and make up the volume up to 
100 ml (Stock Solution II: 100μg/ml). Then the aliquots were 
prepared, whose concentration ranging from 10 to 50 μg/ml and the 
absorbance were measured at 275 nm by using UV Spectro-
photometer (Elico) against the reagent blank. The coefficient of 
variation and correlation coefficient were determined.  
The characteristic parameters of the powders were evaluated (table 
No.2). The angle of repose was determined by the ‘funnel method.' 
The bulk density and tapped density were determined by the 
cylinder method, and Carr’s index was calculated using the following 
equation.  




Characterization of pre-compressed powder blend 
Where, Df= Poured bulk or bulk density, D0 = Tapped or 
consolidated bulk density. 
Preparation of floating-bioadhesive tablets 
All the floating-bioadhesive tablets were fabricated by using direct 
compression technique. HPMC K15M, Gaur gum, Carbopol, Sodium 
alginate, Sodium bicarbonate, Talc, Magnesium Stearate, Citric acid 
and microcrystalline cellulose were blended homogeneously in a 
mortar. The blended mixture was passed through Sieve 60. Finally, 
talc and magnesium stearate was added and blended. The 
homogeneously blended mixture was compressed in a rotary tablet 
press with the 8 mm concaves punch. The tablet hardness was in the 
range 5-6 kg/cm2
Evaluation of tablet 
 tested on Monsanto tablet hardness tester. 
Density measurement of tablet 
The density of tablets was calculated from their volumes and masses 
in triplicate. The volume V of the cylindrical tablets were calculated 
from their height h and radius r (both determined with a Vernier 
caliper) using the mathematical equation for a cylinder (V = π × r 2 × 
h). The tablets with ~1 g/cm3
Determination of floating capacity 
 density or less were chosen for further 
studies [7]. 
Three individual tablets from each formulation were put in an 
individual flask containing 900 ml of 0.1N HCl solutions. Then note the 
time in minutes for each tablet to go from the bottom to the top of the 
flask (floating lag time) and the time for which tablets constantly float 
on the water surface (duration of floating) were measured. The sample 
mean and standard deviation were calculated [8]. 
Swelling characteristics 
The swelling properties of matrices containing drug were 
determined by placing the tablet matrices in the dissolution test 
apparatus, in 900 ml 0.1N HCl at 37±0.5 °C. The tablets were 
removed periodically from the dissolution medium and, after 
removing free water, the weight gain was measured. The swelling 
characteristics were expressed in terms of the percentage water 
uptake (WU %) according to the equation [9]. 
WU% =  
Weight of the swollen tablet — Initial weight of the tablet
Initial weight of the tablet × 100 
Drug content and physical evaluation 
The drug content of the tablets was determined using 0.1N HCl as a 
solvent, and the samples were analyzed spectrophotometrically 
(Shimadzu, SPD-10AVP, Kyoto, Japan). at 224 nm. Tablets were also 
examined with regard to their weight variation (n = 10), friability (n 
= 10) and hardness (n = 3) [10]. 
In vitro bio-adhesion study 
The bioadhesive forces of the bilayer tablets were determined by the 
measuring device shown in fig. 1. Pieces of sheep funds tissue were 
stored frozen in saline solution and thawed to room temperature 
immediately before use. At the time of testing a section of tissue (E) 
was transferred, keeping the mucosal side out, to the upper glass 
vial (C) using a rubber band and an aluminum cap. The diameter of 
each exposed mucosal membrane was 1.1 cm. The vials with the 
funds tissue were stored at 37 °C for 10 min. Next, one vial with a 
section of tissue (E) was connected to the balance (A) and the other 
vial was fixed on a height-adjustable pan (F). A bilayer tablet (D) was 
applied to the lower vial with the help of two pieces of adhesive 
tape. The height of the vial was adjusted so that the tablet could 
adhere to the mucosal tissues in the vial. A constant weight (10 g) 
was placed on the upper vial and applied for 2 min, after which it 
was removed, and the upper vial was then connected to the balance. 
Weights (B) were added at a constant rate to the pan on the other 
side of the modified balance of the device until the two vials were 
separated. The bioadhesive force, expressed as the detachment 
stress in N/M2
Ex vivo mucoadhesive time  
, was determined from the minimum weight required 
to detach the two vials using the following equation [11]. 
Bioadhesive force (N/M2)  =
 m x g
A
 
A modified balance method [12] was used for determining the ex vivo 
Mucoadhesive strength. Fresh sheep mucosa was obtained from a local 
slaughterhouse and used within 2 h of slaughter. The mucosal 
membrane was separated by removing underlying fat and loose 
tissues. The membrane was washed with distilled water and then with 
phosphate buffer pH 6.8 at 37 °C. The sheep buccal mucosa was cut 
into pieces and washed with phosphate buffer pH 6.8. A piece of buccal 
mucosa was tied to the glass vial, which was filled with phosphate 
buffer. The glass vial was tightly fitted into a glass beaker (filled with 
0.1N HCl, at 37 °C±1 °C) so that it just touched the mucosal surface. 
The buccal tablet was stuck to the lower side of a rubber stopper with 
cyanoacrylate adhesive. The two sides of the balance were made equal 
before the study, by keeping a 5-g weight on the right-hand pan. A 
weight of 5 g was removed from the right-hand pan, which lowered 
the pan along with the tablet over the mucosa. The balance was kept in 
this position for 5 min contact time. The water (equivalent to weight) 
was added slowly with an infusion set (100 drops/min) to the right-
hand pan until the tablet detached from the mucosal surface.  
In vitro dissolution studies 
The release rate of Atenolol from floating-bioadhesive tablets was 
determined using USP dissolution testing apparatus II (Paddle type). 
The dissolution test was performed using 900 ml 0.1N HCl, at 37±0.5 °C 
and 50 r/min. A sample (5 ml) of the solution was withdrawn from 
the dissolution apparatus hourly for 12 h, and the samples were 
replaced with fresh dissolution medium. The samples were passed 
through Whatman filter paper, and the absorbance of these 
solutions was measured at 275 nm.  
Stability studies 
The stability studies were carried out according to ICH and WHO 
guidelines [13] to assess the drug and formulation stability. 
Optimized F9 formulations were sealed in aluminum packaging 
having a polyethylene coating on the inside. Samples were kept in a 
humidity chamber maintained at 45 °C and 75% RH for 3 mo. At the 
end of the study period, samples were analyzed for buoyancy lag 
time, ex vivo mucoadhesion time, and bioadhesive force and drug 
release characteristics. 
RESULTS  
Floating-bioadhesive tablets of atenolol were mainly prepared by 
using different polymer like HPMC-K15M, sodium alginate, guar gum 
and Carbo pol either alone or in combination (table 1). The 
compatibility studies provide the framework for the drugs 
combination with excipients in the fabrication of the dosage form. 
No significant change in peak pattern in the IR spectra of pure Drug 
and combination of the drug with polymer indicates no interaction 
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between pure drug and polymer (fig. 1-5). The DSC analysis was 
carried out using Differential Scanning Calorimeter (SDT 2960 TA 
Instrument, USA). Samples were placed in a platinum crucible, and 
the DSC thermo grams were recorded at a heating rate of 10 °C/min 
in the range 20 °C to 350 °C, at a nitrogen flow of 20 ml/min. (fig. 6). 
The effervescent base of tablets was prepared by using sodium 
bicarbonate. The tablets were fabricated using direct compression 
technique. The pre-blended powders were characterized with 
respect to the angle of repose, bulk density, tap density and Carr’s 
index (table 2). 
 
  
Fig. 1: FTIR spectra of Atenolol Fig. 2: FTIR spectra of formulation (F12) 
  
Fig. 3: FTIR spectra of formulation (F10) Fig. 4: FTIR spectra of formulation (F11) 
  
Fig. 5: FTIR spectra of formulation (F9) Fig. 6: DSC of formulation (F9) 
  



















F1 50 70 30 - - 55 65 26 4 
F2 50 75 25 - - 55 65 26 4 
F3 50 80 20 - - 55 65 26 4 
F4 50 70 - 30 - 55 65 26 4 
F5 50 75 - 25 - 55 65 26 4 
F6 50 80 - 20 - 55 65 26 4 
F7 50 70 - - 30 55 65 26 4 
F8 50 75 - - 25 55 65 26 4 
F9 50 80 - - 20 55 65 26 4 
F10 50 70 25 25 - 45 65 26 4 
F11 50 75 - 25 25 45 65 26 4 
F12 50 80 25 - 25 45 65 26 4 
 
HPMC-Hydroxy Propyl Methyl Cellulose, SCMC-Sodium Carboxy Methyl Cellulose, MCC-Micro Crystalline Cellulose, MS-Magnesium Stearate. 
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The Micromeritic properties of the drug and polymers were done by 
evaluating them for the physical characteristics such as Bulk density, 
Tapped density, Compressibility index, Hausner’s ratio and Angle of 
repose. All batches have excellent flow properties.  
The angle of repose for all the batches of powder indicates 
satisfactory flow behavior. Table 2 shows that, as the concentration of 
polymer increases, the angle of repose and Carr’s index increases. The 
formulated tablets were subjected for various evaluation parameters 
like hardness, thickness, density, weight variation, drug content, 
floating capability, Mucoadhesive force, ex-vivo mucoadhesion time 
and dissolution study.  
Our experimental results (table 3) revealed that all the formulated 
tablets were of good quality with regard to hardness (5-  6 kg/m2
 
) 
and drug content (>90%). The floating lag time for all formulations 
was found to be less than 5 min (table 3). Examination of tablets 
from each formulation showed concave shape with no cracks having 
a white color. 
Table 2: Characterization of pre compressed powder blend 
Formulation batches Bulk density(mg/ml)* Tapped density(mg/ml)* Hausner's ratio Carr's index % Angle of repose* 
F1 341±2.0 394±1.8 1.1554 13.45 23.9±1.3 
F2 311±3.2 368±2.8 1.183 15.48 26.1±2.6 
F3 350±2.8 402±1.2 1.148 12.94 25.5±1.5 
F4 350±1.6 410±2.2 1.178 14.63 20.4±1.7 
F5 300±1.2 343±1.6 1.147 12.53 19.5±3.2 
F6 375±1.6 445±1.4 1.187 15.73 26.7±3.3 
F7 468±2.3 538±3.1 1.151 12.32 23±1.4 
F8 416±3.1 482±3.3 1.158 13.69 24.3±1.3 
F9 357±2.1 421±2.3 1.179 18.09 18.5±1.1 
F10 326±2.2 398±2.1 1.221 16.3 24.6±1.2 
F11 341±1.4 407±2.7 1.193 16.21 28±2.1 
F12 349±2.1 431±2.8 1.235 19.02 29±1.7 
Each sample was analyzed in triplicate (n = 3) *mean±SD 
 
The thickness of tablets ranged from 3.22±0.01 to 3.38±0.03. All 
formulations showed uniform thickness. In weight variation test, the 
pharmacopeia limit for percent deviation for tablets of more than 
300 mg is±5%. The average percent deviation of all tablets was 
found to be within limits, and hence all formulations pass the weight 
variation test. The drug content was found to be uniform among all 
formulations 98.19% to 100.85%. the hardness of the tablets was 
found to be between 5.5±0.03 to 5.9±0.01 kg/m. The friability was 
found to be 0.34±0.01% to 0.79±0.03%. 
The muco-adhesion characteristic was found more in F12. This 
formulation contains guar gum and sodium alginate polymers which 
have high adhesion properties (table 4). Swelling index was 
calculated with respect to time (fig. 7). 
 













Ex-Vivo Mucoadhesive time 
(hours) 
F1 5.7±0.3 99.90% 18±0.7 Passes 0.67% 10±0.3 
F2 5.9±0.2 98.39% 13±0.9 Passes 0.68% 10.3±0.1 
F3 5.6±0.4 99.77% 22±1.2 Passes 0.33% 8.1±0.7 
F4 5.8±0.1 100.36% 10±1.7 Passes 0.34% 9.7±0.6 
F5 5.4±0.5 98.33% 19±1.6 Passes 0.68% 10.3±0.4 
F6 5.7±0.3 100.06% 12±0.8 Passes 0.70% 10.7±0.3 
F7 5.8±0.2 98.19% 18±1.6 Passes 0.71% 10.8±0.5 
F8 5.9±0.1 97.41% 52±0.9 Passes 0.68% 9.2±0.6 
F9 5.6±0.3 100.85% 9±0.9 Passes 0.68% 9.8±0.8 
F10 5.5±0.4 99.93% 28±1.2 Passes 0.64% 10.1±0.4 
F11 5.5±0.3 98.72% 14±1.7 Passes 0.67% 11.2±0.9 
F12 5.8±0.1 99.63% 33±1.6 Passes 0.66% 11.5±0.5 
*Each sample was analyzed in triplicate (n = 3) 
 
Table 4: Mucoadhesion study of floating-bioadhesive tablets of atenolol 
Formulations Mucoadhesion value 
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Fig. 7: Swelling index of all formulations 
 
The release of atenolol from bioadhesive floating tablets varied 
according to the type of and concentrations of polymers. 
Formulations F1, F2, and F3 containing drug and guar gum in the 
ratios of 2:1, 1:1 and 2:3 had a % cumulative release of 91.45%, 
86.67% and 87.49% in 12 h respectively. Which showed that guar 
gum was helpful in retarding the drug release (fig. 8). The hydrogel 
were not entangled in the chain of polymers, but discrete microgels 
made up of many polymer particles in which the drug was dispersed. 
The hydrogel remains intact and continuously diffuses through the 
gel layer at a uniform rate. Formulations F4, F5 and F6 containing 
drug and carbopol 974P in the ratios of 2:1, 1:1 and 2:3 had a % 
cumulative release of 85.5%, 90.12% and 91.67% in 12h 
respectively (fig. 9), which shows that the drug was released in a 
controlled manner.  
The hydrogel remains intact when dissolved in water and there was 
a uniform release of the drug. This may be because of high viscosity 
and less solubility. Formulations F7, F8, and F9 containing drug and 
sodium alginate in the ratios of 2:1, 1:1 and 2:3 had a cumulative 
drug release of 96.04%, 96.17% and 99.12% in 12h respectively. The 
release profile was shown in fig. 22. These formulations showed faster 
release than Carbopol 940P and guar gum formulations, this might be 
due to the low viscosity of the polymer (fig. 10). Formulations F10 
containing drug, guar gum and sodium alginate formulation F11 
containing drug, guar gum and Carbopol and F12 containing drug, 
sodium alginate and Carbopol in the ratios of 2:1:1, 2:1:1 and 2:1:1 
respectively showed % cumulative release of 93.92%, 94.43% and 
94.22% in 12h respectively and the results shown in fig. 11. 
Formulation F9 contains polymer sodium alginate which has shown 
highest % cumulative drug release up to 99.12%. 
 
 
Fig. 8: Dissolution profile of formulations F1, F2, F3 
 
Results of stability studies of formulation F9 indicate that it is stable 
at 40 °C,75%±5% relative humidity as there was no significant 
difference observed for dissolution, floating time Mucoadhesive 
force and ex-vivo mucoadhesion time.(fig. 12 and 13). 
 
Fig. 9: Dissolution profile of formulations F4, F5, F6 
 
 
Fig. 10: Dissolution profile of formulations F7, F8 and F9 
 
 
Fig. 11: Dissolution profile of formulations F10, F11, F12 
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Fig. 13: Comparative mucoadhesion, Buoyancy lag time and ex 
vivo mucoadhesive time study of batch F9 after stability period 
 
DISCUSSION 
Observations of all formulations for physical characterization had 
shown that, all of them comply with the specifications of official 
pharmacopeia and standard reference. Results of floating behavior 
indicated that all batches show floating time less than a minute and 
floating duration for more than 12 h. Results of swelling 
characteristics and in vitro dissolution study indicated that batch 
(F9) was having considerable swelling index and desirable 
dissolution. Inter-particulate interactions that influence the bulking 
properties of a powder are powder flow. A comparison of bulk 
density and tapped density can give a measure of the relative 
importance of this in a given powder; such a comparison is often 
used as an index of the ability of the powder flow. From the study it 
was found that maximum liquid uptake and swelling of the polymer 
was achieved up to 10hr and then gradually decreased. Maximum 
swelling was observed in formulation (F9). It was also observed that 
cumulative drug release increased when the viscosity and 
concentration of the polymer was increased.  
From previous work [14] on the gastro retentive floating tablet of 
atenolol it was concluded that the swelling index may be increased 
as the concentration of guar gum increases, but in the present work 
it was found out that the swelling index may directly relates the 
viscosity as well as the concentration of the polymers. 
From previous work [15] it was mentioned the floating lag time 
gradually decreases with increase in concentration of sodium 
bicarbonate, but in the present work it was found that the floating 
lag time may also depend upon the concentration, type as well as the 
viscosity of the polymer used.  
CONCLUSION 
From the research work it was concluded that batch F9 had 
considerable floating and swelling behaviors with good release 
pattern. Tablets of batch F9 were selected as optimum batch. 
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